At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AZTR Azitra Inc
Pre-Mkt 02-18 06:15:40 EST
0.1690
-0.0308
-15.42%
High0.2000Low0.1610Vol2.77M
Open0.2000D1 Closing0.1998Amplitude19.52%
Mkt Cap1.82MTradable Cap910.37KTotal Shares10.74M
T/O488.61KT/O Rate51.43%Tradable Shares5.39M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Azitra Inc. to Hold Reconvened Special Meeting on March 6, 2026, to Vote on Proxy Proposals After Previous Lack of Quorum
Reuters  ·  02-07
Azitra Inc. to Hold Reconvened Special Meeting on March 6, 2026, to Vote on Proxy Proposals After Previous Lack of Quorum
Azitra Inc. to Present Clinical Strategy at Biotech Showcase in San Francisco
Reuters  ·  01-07
Azitra Inc. to Present Clinical Strategy at Biotech Showcase in San Francisco
Azitra Inc. Announces Date for Upcoming Special Meeting of Stockholders
Reuters  ·  2025-12-24
Azitra Inc. Announces Date for Upcoming Special Meeting of Stockholders
BRIEF-Azitra Receives Notice Of Acceptance Of The Listing Standards Compliance Plan From NYSE American
Reuters  ·  2025-12-18
BRIEF-Azitra Receives Notice Of Acceptance Of The Listing Standards Compliance Plan From NYSE American
Azitra Faces NYSE American Listing Compliance Deadline
Reuters  ·  2025-12-18
Azitra Faces NYSE American Listing Compliance Deadline
Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan From Nyse American
THOMSON REUTERS  ·  2025-12-18
Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan From Nyse American
Azitra Inc Secures $1.5M in Private Placement
TIPRANKS  ·  2025-11-26
Azitra Inc Secures $1.5M in Private Placement
Press Release: Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules
Dow Jones  ·  2025-11-24
Press Release: Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules
Anitra Q3 EPS $(0.67) Beats $(0.78) Estimate
Benzinga  ·  2025-11-13
Anitra Q3 EPS $(0.67) Beats $(0.78) Estimate
Press Release: Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates
Dow Jones  ·  2025-11-13
Press Release: Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates
Azitra posts Q3 net loss of $2.8 million on $1.4 million cash balance
Reuters  ·  2025-11-13
Azitra posts Q3 net loss of $2.8 million on $1.4 million cash balance
BRIEF-Azitra, Inc. Addresses False Report Regarding Sale Of Securities
Reuters  ·  2025-11-07
BRIEF-Azitra, Inc. Addresses False Report Regarding Sale Of Securities
Azitra Inc - Taking Steps to Identify Source of False Report
THOMSON REUTERS  ·  2025-11-07
Azitra Inc - Taking Steps to Identify Source of False Report
Azitra - Report Circulated Claiming That Co Priced a $44 Million Registered Direct Offering Is False and Should Not Be Relied Upon
THOMSON REUTERS  ·  2025-11-07
Azitra - Report Circulated Claiming That Co Priced a $44 Million Registered Direct Offering Is False and Should Not Be Relied Upon
Azitra Unveils Positive Preclinical Results for ATR-01 in Ichthyosis Vulgaris
Reuters  ·  2025-10-20
Azitra Unveils Positive Preclinical Results for ATR-01 in Ichthyosis Vulgaris
Azitra- Atr-01 Preclinical Data Show Production of Active, Functional Filaggrin Delivered Through Human Stratum Corneum & Repair of Damaged Model Skin
THOMSON REUTERS  ·  2025-10-20
Azitra- Atr-01 Preclinical Data Show Production of Active, Functional Filaggrin Delivered Through Human Stratum Corneum & Repair of Damaged Model Skin
Azitra, Inc. Announces Positive Preclinical Data for Atr-01 Program, Designed to Treat Ichthyosis Vulgaris
THOMSON REUTERS  ·  2025-10-20
Azitra, Inc. Announces Positive Preclinical Data for Atr-01 Program, Designed to Treat Ichthyosis Vulgaris
Azitra Inc Faces NYSE Compliance Deadline Notice
TIPRANKS  ·  2025-10-04
Azitra Inc Faces NYSE Compliance Deadline Notice
Azitra Inc. Receives NYSE American Non-Compliance Notice Over Stockholders’ Equity Requirements
Reuters  ·  2025-10-04
Azitra Inc. Receives NYSE American Non-Compliance Notice Over Stockholders’ Equity Requirements
Azitra receives noncompliance notification from NYSE
TIPRANKS  ·  2025-10-04
Azitra receives noncompliance notification from NYSE

Introduction

Company Name.
Azitra Inc
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
Issue price:
--